Abbott (ABT) Shares Jump on FDA Deal to Restart Michigan Baby Formula Plant in as Little as 2 Weeks
- Stocks tumble after weak U.S. confidence data; oil gains
- Earnings Estimates are 'Likely Too Optimistic', Risk Not Fully Reflected - Goldman
- Pinterest (PINS) CEO Silbermann Is Stepping Down, Shares Gain 8%
- Apple's (AAPL) Runs into 5G Modem Development Issues, Will Continue to Use Qualcomm (QCOM) - Analyst
- Bank of America Clients are Selling This Rally
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Abbott (NYSE: ABT) shares are gaining over 4% in mid-day trading Tuesday after the company enter into a consent decree with the FDA on steps to resume production at its troubled infant formula plant in Sturgis, Mich. The shutdown of the plant, due to suspected links to infant illnesses, has contributed to the national crisis of infant formula shortages.
"Our number one priority is getting infants and families the high-quality formulas they need, and this is a major step toward re-opening our Sturgis facility so we can ease the nationwide formula shortage," Abbott CEO Robert Ford commented.
The plant could restart within two weeks after the FDA confirms the initial requirements for start-up have been met.
One authorized, Abbott said it would begin production of EleCare, Alimentum and metabolic formulas first and then begin production of Similac and other formulas.
A thorough investigation by FDA, Centers for Disease Control and Prevention (CDC) and Abbott there is no conclusive evidence to link Abbott's formulas to these infant illnesses.
The consent decree between Abbott and the FDA is subject to court approval.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jazz Pharmaceuticals (JAZZ) Phase 3 Trial Evaluating Nabiximols Oromucosal Spray Did Not Meet Primary Endpoint
- FTC Sues Walmart for Facilitating Money Transfer Fraud Resulting in Loss of Hundreds of Millions
- ObsEva SA (OBSV) Announces UK Marketing Authorization for Yselty
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot List
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!